VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 355 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2013. The put-call ratio across all filers is 0.61 and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $98,000 | -23.4% | 8,842 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $128,000 | -41.0% | 8,842 | 0.0% | 0.00% | -50.0% |
Q3 2016 | $217,000 | +21.9% | 8,842 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $178,000 | +71.2% | 8,842 | +121.9% | 0.00% | +100.0% |
Q1 2016 | $104,000 | -99.8% | 3,985 | -98.9% | 0.00% | -99.9% |
Q3 2015 | $63,273,000 | +713.8% | 353,632 | +908.6% | 0.80% | +846.4% |
Q2 2015 | $7,775,000 | +19.0% | 35,060 | +5.8% | 0.08% | +18.3% |
Q1 2015 | $6,536,000 | +19.6% | 33,138 | -13.2% | 0.07% | +22.4% |
Q4 2014 | $5,467,000 | -2.0% | 38,188 | -10.3% | 0.06% | 0.0% |
Q3 2014 | $5,581,000 | -5.6% | 42,588 | -8.9% | 0.06% | 0.0% |
Q2 2014 | $5,912,000 | -2.7% | 46,753 | +1.3% | 0.06% | -6.5% |
Q1 2014 | $6,075,000 | -59.1% | 46,153 | -63.5% | 0.06% | -59.2% |
Q4 2013 | $14,846,000 | +7.3% | 126,553 | -4.7% | 0.15% | -2.6% |
Q3 2013 | $13,836,000 | +13.5% | 132,803 | -6.1% | 0.16% | +10.6% |
Q2 2013 | $12,189,000 | – | 141,403 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |